<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Alpha-1-receptor antagonists used to treat lower urinary tract symptoms due to benign prostatic hyperplasia (BPH)</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Medication</td> <td class="subtitle1" colspan="2">Dose<sup>*</sup></td> <td class="subtitle1">Administration</td> </tr> <tr class="divider_bottom"> <td>Alfuzosin (Uroxatral, Xatral)</td> <td>Initial and maintenance</td> <td>10 mg</td> <td>Once daily immediately following a meal at the same time each day</td> </tr> <tr class="divider_bottom"> <td>Silodosin (Rapaflo)</td> <td>Initial and maintenance</td> <td>8 mg</td> <td>Once daily with a meal at the same time each day</td> </tr> <tr> <td class="divider_bottom" rowspan="2">Tamsulosin (Flomax)</td> <td>Initial and maintenance</td> <td>0.4 mg</td> <td class="divider_bottom" rowspan="2">Once daily approximately 30 minutes after a meal at the same time each day; 0.8 mg dose may be administered as 0.4 mg twice daily</td> </tr> <tr class="divider_bottom"> <td>If inadequate response after 2 to 4 weeks</td> <td>0.8 mg</td> </tr> <tr class="divider_bottom"> <td> <p>Tamsulosin extended-release (Flomax CR)</p> (NOTE: formulation available in some countries other than the United States)</td> <td>Initial and maintenance</td> <td>0.4 mg</td> <td>Once daily with a meal at the same time each day; maximum dose 0.4 mg once daily</td> </tr> <tr class="divider_bottom"> <td colspan="4"> <p><strong>Conventional agents:</strong> Titration recommended to reduce orthostatic effects</p> Dose is advanced as shown if patient remains symptomatic and is tolerating current dose</td> </tr> <tr> <td class="divider_bottom indent1" rowspan="4">Doxazosin immediate-release (Cardura)</td> <td>Days 1 to 3</td> <td>1 mg</td> <td class="divider_bottom" rowspan="4">Once daily at bedtime</td> </tr> <tr> <td>Days 4 to 14</td> <td>2 mg</td> </tr> <tr> <td>Weeks 2 to 6</td> <td>4 mg</td> </tr> <tr class="divider_bottom"> <td>Week 7 and thereafter</td> <td>8 mg</td> </tr> <tr> <td class="divider_bottom indent1" rowspan="2">Doxazosin extended-release (Cardura XL)</td> <td>Days 1 to 21</td> <td>4 mg</td> <td class="divider_bottom" rowspan="2">Once daily with morning meal</td> </tr> <tr class="divider_bottom"> <td>Week 4 and thereafter</td> <td>8 mg</td> </tr> <tr> <td class="indent1" rowspan="12">Terazosin (Hytrin)</td> <td colspan="3"><strong>Standard titration (appropriate for most patients)</strong></td> </tr> <tr> <td class="indent1">Days 1 to 3</td> <td>1 mg</td> <td class="divider_bottom" rowspan="5">Once daily at bedtime</td> </tr> <tr> <td class="indent1">Days 4 to 14</td> <td>2 mg</td> </tr> <tr> <td class="indent1">Weeks 2 to 6</td> <td>5 mg</td> </tr> <tr> <td class="indent1">Week 7 and thereafter</td> <td>10 mg</td> </tr> <tr class="divider_bottom"> <td class="indent1">If inadequate response after 4 to 6 weeks of 10 mg/day</td> <td>20 mg</td> </tr> <tr> <td colspan="3"><strong>Rapid titration (for selected patients)</strong></td> </tr> <tr> <td class="indent1">Days 1 to 3</td> <td>1 mg</td> <td rowspan="5">Once daily at bedtime</td> </tr> <tr> <td class="indent1">Days 4 to 14</td> <td>2 mg</td> </tr> <tr> <td class="indent1">Weeks 2 to 3</td> <td>5 mg</td> </tr> <tr> <td class="indent1">Week 4 and thereafter</td> <td>10 mg</td> </tr> <tr> <td class="indent1">If inadequate response after 4 to 6 weeks of 10 mg/day</td> <td>20 mg</td> </tr> </tbody></table></div><div class="graphic_lgnd"><ul>
<li>Dosing recommendations are for oral administration in adult patients with normal organ function. Titration schedules are examples; other regimens may be appropriate. For recommendations on clinical use and individualizing drug selection, refer to the clinical topic review of BPH and individual drug information topics.</li>
<li>Alpha-1-receptor antagonists may have additive hypotensive effects with phosphodiesterase-5 inhibitors (eg, sildenafil) and other agents that lower blood pressure. For specific drug interactions, refer to the <a href="https://www.uptodate.com/drug-interactions">Lexicomp drug interactions</a> database included within UpToDate.</li>
<li>Dosing recommendations for other agents used to treat lower urinary tract symptoms due to BPH is available in a separate table within UpToDate.</li>
</ul></div><div class="graphic_footnotes">* If therapy is interrupted for 3 or more days, reinitiate at lowest dose and retitrate according to schedule.</div><div class="graphic_reference">Data from:
<ol>
<li>Lee M. Management of benign prostatic hyperplasia. In: Pharmacotherapy, 7th ed, Dipiro JT, Talbert RL, Yee GC, et al (Eds), McGraw-Hill Medical 2008.</li>
<li>Lexicomp Online. Copyright Â© 1978-2024 Lexicomp, Inc. All Rights Reserved.</li>
<li>AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 2003; 170:530.</li>
</ol></div><div id="graphicVersion">Graphic 129672 Version 12.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
